The Open AIDS Journal




ISSN: ― Volume ,
RESEARCH ARTICLE

Assessment of the Effect of HAART on Renal Function of HIV Patients Attending the Bamenda Regional Hospital, Cameroon



Achu C. A. Nforbugwe1, 2, *, Acha E. Asongalem1, Bihnwi R. Nchotu1, Elvis A. Tanue3, Frankline S. Wirsiy2, 3, Nguedia J. C. Assob1
1 Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Buea, P.O. Box 63-Buea, Cameroon
2 Global Health Systems Solutions (GHSS), Denver layout, Bonamoussadi, P.O, Box. 3918 Douala, Littoral Region, Cameroon
3 Department of Public Health and Hygiene, Faculty of Health Sciences, University of Buea, P.O. Box 63 - Buea, Cameroon

Abstract

Background:

Management of HIV involves a life-long administration of a cocktail of antiretroviral drugs, some of which have been known for their nephrotoxicity. Despite the increasing access to this combination therapy, Highly Active Antiretroviral Therapy (HAART) information on its renal effect is still scarce and contradictory. The aim of this study was to assess the effect of HAART on the renal function of HIV-infected patients attending the Bamenda Regional Hospital, Cameroon.

Methods:

This was a comparative hospital-based cross-sectional study involving HIV positive and negative individuals who visited the Day clinic of the Bamenda Regional Hospital during the study period. Spectrophotometry was used to quantify the renal markers. Glomerular Filtration Rate was determined by the 24 hours creatinine clearance method. Blood urea nitrogen was calculated from serum urea concentrations. Renal impairment was then classified according to the National Kidney Foundation clinical practice guideline. Data were analysed on SPSS version 21 using Student t-test, ANOVA, and Pearson’s correlation. The level of significance was set at p<0.05.

Results:

A total of 201 participants were enrolled in this study, of which 144(71.6%) were females. Their ages ranged between 22 to 60 years with a mean age of 37.4 ± 9.6 years. The participants were divided into 3 study groups; HIV negative, HAART-naïve and the HAART experienced groups. The HAART experienced group had a significantly higher mean BUN and BUN-Creatinine ratio (p= 0.001 and 0.003 respectively) as well as the least creatinine clearance (p= 0.017) when compared to the other groups meanwhile the HAART-naive group had a significantly higher mean urine protein (p= 0.026) when compared to the other two categories. There was no association between renal dysfunction and the HAART regimen as well as adherence to treatment.

Conclusion:

This study demonstrated that though the participants on HAART had decreased renal function, the mean Creatinine clearance was not statistically different from that of the participants not yet on HAART. this is indicative that the decreased renal function could be as a result of the devastating effect of HIV. It further demonstrates no association between decreased renal function to the type of HAART regimen used, duration on HAART as well as the patient’s adherence to treatment.

Keywords: HAART, Renal Dysfunction, Creatinine clearance, HIV/AIDS, WHO, Spectrophotometry.


Article Information


Identifiers and Pagination:

Year: 2020
Volume: 14
First Page: 1
Last Page: 9
Publisher Id: TOAIDJ-14-1
DOI: 10.2174/1874613602014010001

Article History:

Received Date: 22/07/2019
Revision Received Date: 31/12/2019
Acceptance Date: 08/01/2020
Electronic publication date: 18/02/2020
Collection year: 2020

© 2020 Nforbugwe et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


* Address correspondence to this author at the Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Buea, P.O. Box 63-Buea; Cameroon, Tel: +237672378156; E-mail: niawah95@gmail.com



Track Your Manuscript:


Endorsements



"Publishing with Bentham Open was a great experience. The timeliness and communication were outstanding. I am hopeful that I will have the opportunity to publish with Bentham Open again in the future."


Dr. Daniel B. Chastain
Pharm.D., AAHIVP, Clinical Pharmacy Specialist, Infectious Diseases, Phoebe Health, USA


SCImago Journal Ranking

SCImago Journal & Country Rank

Browse Contents



Webmaster Contact: info@benthamopen.net
Copyright © 2020 Bentham Open